Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: Data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803

D. Sargent, Q. Shi, G. Yothers, E. Van Cutsem, J. Cassidy, L. Saltz, N. Wolmark, B. Bot, A. Grothey, M. Buyse, A. De Gramont

Research output: Contribution to journal › Article › peer-review

83 Scopus citations

Fingerprint

Dive into the research topics of 'Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: Data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803'. Together they form a unique fingerprint.

Medicine & Life Sciences